IDWeek 2023: Shionogi and Qpex Biopharma, Inc. Continue Long

IDWeek 2023: Shionogi and Qpex Biopharma, Inc. Continue Longstanding Commitment to Addressing Unmet Needs in Infectious Disease

FLORHAM PARK, N.J., September 07, 2023--Shionogi Inc., the United States subsidiary of Shionogi & Co., Ltd., (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.), announced the upcoming presentation of new data at IDWeek 2023 (October 11-15, 2023) on its investigational oral antiviral for COVID-19, ensitrelvir (Generic name: ensitrelvir fumaric acid, Code No.: S-217622, hereafter "ensitrelvir"), and Fetroja® (cefiderocol), an antibiotic marketed under the brand name Fetcro

Related Keywords

Japan , Osaka , United States , Japanese , David Nicolau , Isao Teshirogi , Olga Lomovskaya , Shionogi Co Ltd , Head Office , Antimicrobial Surveillance Program , Qpex Biopharma Inc , Global Antibiotic Research , Surveillance Program , Clinton Health Access Initiative , Development Partnership , Shionogi Inc , Chief Executive Officer , Qpex Biopharma , Senior Vice President , Clinical Microbiology , Pipeline Part , Japanese Clinical Practice , Post Marketing Surveillance , Interim Analysis , Taste Disorder , Smell Disorder , Combined Results , Controlled Trials , Population Pharmacokinetic Analysis , Severe Acute Respiratory Syndrome Coronavirus , Infections Treated , Retrospective Cefiderocol Chart Review , First Dose , Cefiderocol Use , Treating Patients , Confirmed Stenotrophomonas , During January , Real World Use , Cefiderocol Treating , Confirmed Gram Negative Infections , United States Hospitals , Cefiderocol Activity Against Multidrug Resistant , Molecularly Characterized Pseudomonas , Clinical Isolates Causing Infection , Comparator Agents Against Difficult , Treat Resistance , Gram Negative Isolates , Collected During , Comparator Agents Against Achromobacter , Burkholderia Isolates , Comparator Agents Against Pediatric Isolates , Infection Type , Antimicrobial Activity , Comparator Agents Against Isolates , Determining Effect , Disk Source , Broth Microdilution , Disk Diffusion Testing , Learning Lounge , Clinical Data , Industry Education Evening , Medicines Patent Pool , Full Prescribing Information , Important Safety Information , Shionogi , Stenotrophomonas Maltophilia , Poster , Pseudomonas Aeruginosa ,

© 2025 Vimarsana